MHRA unveils ambitious 2030 strategy

This comprehensive plan commits to ensuring that the regulator keeps pace with the rapid evolution of science, technology, and personalised healthcare. The ultimate goal of the strategy is to position the UK as a global leader in the safe and effective development, launch, and usage of new medicines and technologies.

By the year 2030, the MHRA plans to focus more intently on being patient-centred, enabling quicker access to safe and effective treatments, and enhancing data connectivity, alongside establishing a greater global influence. David Hill, Partner specialising in healthcare regulation at UK and Ireland law firm Browne Jacobson, commented, “A regulator that keeps pace with AI-driven innovation, moves faster on clinical trial approvals and reduces barriers for rare disease and start-up developers is precisely what is required if the UK is to meet the ambitions set out in the NHS 10 Year Health Plan.”

He also noted that the government's three-pillar transition—moving from hospital to community, from sickness to prevention, and from analogue to digital—“can’t succeed without a regulatory infrastructure that safely and effectively embraces innovation, and this strategy begins to build that.” The welcome acknowledgement that regulatory agility is essential for patient benefit was echoed in Hill's remarks on accelerating access to generic and biosimilar medicines, which directly influences the financial sustainability of the NHS.

Furthermore, the anticipated AI Medicines Development Action Plan and Centre for AI and Digital Health could potentially provide developers and investors with the assurance needed to select the UK as their launch market. As Hill pointed out, “Increasing diversity in clinical studies can further strengthen the UK’s potential to become a hotbed for rolling out novel technologies due to its cradle-to-grave records held by the NHS, a diverse population, and strong links between health information and the research community.”

However, Hill warns that while the MHRA's reforms are critical, they represent just a segment of the more intricate challenges the UK faces. He stated, “Our work with international investors and NHS partners tells us that regulatory reform at the MHRA level is only one piece of a considerably more complex puzzle.” In their white paper on advancing investment in the UK health sector, they highlighted regulatory complexity and fragmented procurement pathways as significant hurdles to international investment.

For the MHRA's reforms to be truly impactful, Hill advocates for the acceleration of the aggregation and integration of primary, secondary, community, and social care datasets, while also emphasising the need to address regulatory and legal barriers to international data sharing. He sees promise in the MHRA's commitment to real-world evidence generation and its connection with the Health Data Research Service, but insists this must be supported by a coherent UK health data strategy that provides legal certainty for both domestic and international partners.

Additionally, Hill remarked on the importance of credibility in strategy documents, noting, “A strategy document, however well-crafted, is only as credible as the resource commitment behind it.” He urges the government to ensure that the MHRA's funding model evolves alongside the ambitious targets established in the strategy, especially given the new responsibilities it entails.

In conclusion, the MHRA 2030 Strategy sets an elevated standard for what is possible within the UK's healthcare landscape. The essential next step is establishing the necessary foundations to achieve these ambitious goals.